Coya Therapeutics Announces Issuance of New Patent Protecting Methods of Producing Recombinant Human Interleukin-2 Liquid Formulations
Coya Therapeutics, Inc. recently announced the issuance of a US patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the US Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of IL-2 (aldesleukin). Through an existing agreement, Coya has the exclusive in-vivo rights to this patent and other related intellectual property spanning multiple indications both as monotherapy and combination therapies.
Arun Swaminathan, PhD, CEO of Coya, said “The issuance of this in-licensed patent sets a strong milestone in the history of Coya. Our investigational low-dose rhIL-2 (COYA 301) is a key asset of Coya’s pipeline. This patent serves as only one component of a growing, broader, and layered IP portfolio involving combinations with other biologics – such as Coya’s combinations with CTLA-4 Ig (COYA 302) and GLP-1 agonists (COYA 303) that we believe, adds a broader moat of protection to the portfolio. We plan to continue to expand and enhance the IP portfolio.”
COYA 301, COYA 302, and COYA 303 are each an investigational product candidate not yet approved by the US FDA.
Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.
Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information, visit www.coyatherapeutics.com.
Total Page Views: 488
